Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies
出版年份 2014 全文链接
标题
Effects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume 21, Issue 3, Pages R247-R259
出版商
Bioscientifica
发表日期
2014-01-30
DOI
10.1530/erc-12-0400
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors
- (2013) Ellin Berman et al. LEUKEMIA RESEARCH
- Imatinib mesylate induces massive and nonspecific aminoaciduria in cml patients
- (2012) Jean-Christophe Ianotto et al. AMERICAN JOURNAL OF HEMATOLOGY
- Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study
- (2012) Rosemary A. Hannon et al. BONE
- Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
- (2012) B Beuselinck et al. BRITISH JOURNAL OF CANCER
- Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
- (2012) Laurence Albiges et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma
- (2012) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia-driven pathways in bone development, regeneration and disease
- (2012) Christa Maes et al. Nature Reviews Rheumatology
- Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration
- (2012) A. Berruti et al. ONCOLOGIST
- Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
- (2012) Antonio Garcia-Gomez et al. PLoS One
- Hepatocyte Growth Factor Increases Osteopontin Expression in Human Osteoblasts through PI3K, Akt, c-Src, and AP-1 Signaling Pathway
- (2012) Hsien-Te Chen et al. PLoS One
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Sunitinib-induced hyperparathyroidism
- (2011) Valentina Baldazzi et al. CANCER
- Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function
- (2011) Shinya Maita et al. INTERNATIONAL JOURNAL OF CANCER
- Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro
- (2011) Sofia Jönsson et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer
- (2011) Maryse Brassard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
- (2011) F. Dayyani et al. JNCI-Journal of the National Cancer Institute
- The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
- (2011) Adriana Borriello et al. PLoS One
- Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
- (2011) Evan Y. Yu et al. UROLOGY
- The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts
- (2010) Hichame Id Boufker et al. BMC CANCER
- Imatinib Mesylate Does Not Increase Bone Volume In Vivo
- (2010) Susannah O’Sullivan et al. CALCIFIED TISSUE INTERNATIONAL
- Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate
- (2010) Kyu-Hyun Yang et al. JOURNAL OF BONE AND MINERAL METABOLISM
- The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo
- (2010) Kate Vandyke et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes
- (2010) Dori Bilik et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
- (2010) Maria E. Cabanillas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
- (2010) Elaine T. Lam et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study
- (2010) Sami Antoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- Dysregulation of bone remodeling by imatinib mesylate
- (2009) K. Vandyke et al. BLOOD
- Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF
- (2009) Ernestina Schipani et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial
- (2009) Rosemary A Hannon et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Decreased Bone Turnover Despite Persistent Secondary Hyperparathyroidism during Prolonged Treatment with Imatinib
- (2009) Susannah O'Sullivan et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers
- (2009) Steven I. Sherman JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sarcopenia: etiology, clinical consequences, intervention, and assessment
- (2009) T. Lang et al. OSTEOPOROSIS INTERNATIONAL
- Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss
- (2008) Helene François et al. AMERICAN JOURNAL OF KIDNEY DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now